Clinical Trial

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To find out if a combination of fruquintinib and tislelizumab can control CRC in patients who have received treatment for the disease but still have "positive" ctDNA tests for MRD (meaning there is evidence of MRD based on this test).
Protocol Amendment History 3 changes
critical Enrollment closed, study ongoing 2026-08-01
notable Enrollment reduced: 20 -> 15 participants 2026-08-01
notable Primary completion pushed: 2026-04-01 -> 2027-12-01 2026-04-07
Trial Details
NCT Number NCT07136077
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: BeiGene, Takeda Pharmaceutical Co. Limited
Conditions Minimal Residual Disease, Adjuvant Chemotherapy, Colorectal Cancer, Fruquintinib, Tislelizumab, ctDNA
Enrollment 15 participants
Start Date 2025-09-18
Primary Completion 2027-12-01 (estimated)
Study Completion 2028-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-12